Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Mouse (GM-CSF, Colony-stimulating Factor, CSF, Colony Stimulating Factor 2 (Granulocyte-macrophage), Csf2, Csfgm, MGC151255, MGC151257, MGI-IGM)

Source:\nRecombinant corresponding to 125aa of mouse Granulocyte Macrophage-Colony Stimulating Factor expressed in E.coli is a single, non-glycosylated, polypeptide chain.\n\nMolecular Weight:\n~14.3kD\n\nBiological Activity:\nThe ED50 as determined by the dose-dependent stimulation of the proliferation of mouse FDC-P1 cell line is less then 0.2ng/ml, corresponding to a Specific Activity of 5x10 6IU/mg.\n\nDimers and Aggregates:\n(same/less than)1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods: 1.UV spectroscopy at 280nm using the absorbency value of 0.765 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of GM-CSF as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

G8951-25M

Size

10ug

Form

Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug (IEU/ug)

References

1. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect Immun 2005 Nov;73(11):7450-7. 2. Serum profiles of circulating granulocyte-macrophage colony-stimulating factor in acute myocardial infarction and relation with post-infarction left ventricular function. Chin Med J (Engl) 2005 Sep 20;118(18):1557-9. 3. Comparison of the activities of granulocyte-macrophage colony-stimulating factor and interleukin-8 secretion between two lung epithelial cell lines. J Microbiol Immunol Infect 2005 Oct;38(5):327-31. 4. Nonobese diabetic mouse congenic analysis reveals chromosome 11 locus contributing to diabetes susceptibility, macrophage STAT5 dysfunction, and granulocyte-macrophage colony-stimulating factor overproduction. J Immunol 2005 Oct 1;175(7):4561-5. 5. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating fact or vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005 Nov;19(11):1929-33. 6. [Granulocyte-macrophage colony-stimulating factor]. Nippon Rinsho 2005 Aug;63 Suppl 8:51-3.

Alternative Names

Granulocyte-macrophage Colony-stimulating Factor